Increasing Transparency in Generic Drug Applications Act of 2022
USA117th CongressHR-7032| House
| Updated: 3/10/2022
Ann M. Kuster
Democratic Representative
New Hampshire
Cosponsors (1)
Health Subcommittee, Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Increasing Transparency in Generic Drug Applications Act of 2022 This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Health
Administrative law and regulatory proceduresDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationPrescription drugs
Increasing Transparency in Generic Drug Applications Act of 2022
USA117th CongressHR-7032| House
| Updated: 3/10/2022
Increasing Transparency in Generic Drug Applications Act of 2022 This bill requires the Food and Drug Administration to inform generic drug applicants, upon request or during review, whether the drug is qualitatively and quantitatively the same as the listed brand-name drug (and if not, the reasons why).
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Referred to the Subcommittee on Health.
Ann M. Kuster
Democratic Representative
New Hampshire
Cosponsors (1)
Health Subcommittee, Energy and Commerce Committee
Health
Related Bills
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Administrative law and regulatory proceduresDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationPrescription drugs